Getting a prescription for a GLP-1 medication covered by insurance is often a separate process from getting the prescription itself. Because drugs like semaglutide and tirzepatide carry high list prices and are prescribed to a very large potential patient population, most health plans attach extra approval steps before they'll pay a claim. This is general background on how that process typically works, not insurance or legal advice, and not a guarantee of any particular outcome — every plan's rules are different, and a patient's own insurer, pharmacy benefit manager, and employer plan documents are the actual source of truth for their situation.
What Prior Authorization Actually Is
Prior authorization (often abbreviated "PA") is a requirement that a prescriber submit clinical documentation to the insurer before the plan will pay for a drug, rather than the pharmacy simply filling it. For GLP-1 medications, insurers commonly ask for documentation such as a patient's body mass index, relevant diagnosis codes (type 2 diabetes versus a weight-management indication), a record of other weight-management approaches already tried, and sometimes specific lab values. Health plans use prior authorization both to confirm that a drug is being used consistently with its FDA-approved indication and, candidly, to manage their own costs on an expensive drug class.
Common Reasons a Claim Gets Denied
Denials tend to cluster around a handful of recurring issues: the plan's formulary doesn't include the specific drug at all (a plan might cover one GLP-1 brand but not a competitor); the patient's BMI or diagnosis doesn't meet the plan's documented threshold; the plan requires "step therapy," meaning the patient must try and fail a cheaper option first; the prescriber's paperwork is incomplete or uses the wrong diagnosis code; or the plan categorically excludes weight-management drugs from coverage, which is still common in many commercial and employer plans even though coverage for diabetes indications is usually broader.
What an Appeal Typically Involves
Most insurers offer at least two levels of appeal. An internal appeal asks the same insurance company to reconsider its own denial, usually with additional clinical documentation from the prescriber — things like more detailed weight and comorbidity history, notes on prior treatments that didn't work, or a letter of medical necessity. Many plans also allow a "peer-to-peer" review, where the prescribing clinician can speak directly with a medical reviewer at the insurance company to explain the clinical reasoning. If an internal appeal fails, many states and most employer plans allow an external review by an independent third party not affiliated with the insurer, whose decision is often binding on the plan. Timelines and exact procedures vary by state and by whether a plan is fully insured, self-funded, or a Medicare or Medicaid plan, so patients generally need to check their own plan's explanation of benefits or summary plan description for exact deadlines.
A Note on Medicare and Medicaid Specifically
Coverage rules for Medicare and Medicaid beneficiaries have been shifting. CMS has been running the Medicare GLP-1 Bridge, a time-limited demonstration giving some Part D beneficiaries access to certain GLP-1 drugs, running from mid-2026 through the end of 2027, alongside a separate, broader voluntary model (branded BALANCE) that lets state Medicaid agencies and Part D plan sponsors opt into negotiated coverage terms for several GLP-1 products, with state Medicaid participation phasing in during 2026. Both programs still allow for prior authorization requirements to apply, and neither guarantees coverage for every beneficiary — eligibility depends on the specific state, plan, and diagnosis. Anyone on Medicare or Medicaid should ask their plan directly whether it has opted into either program rather than assuming coverage based on general news about these initiatives.
What Patients Can Generally Do
Keeping organized records helps: copies of the denial letter (which should state the specific reason), weight and lab trends over time, documentation of other weight-management methods tried, and clear notes from the prescriber connecting the drug to the specific FDA-approved indication being treated. Many prescribers' offices have staff who handle prior authorizations and appeals routinely and can advise on plan-specific requirements. Manufacturer savings programs can sometimes lower out-of-pocket costs for patients with commercial insurance, though these programs typically aren't available to patients on Medicare or Medicaid due to federal anti-kickback rules.
None of this changes the underlying medical decision about whether a GLP-1 medication is appropriate for a given patient — that remains a conversation between a patient and their prescribing physician, who can also advise on alternative options if insurance coverage isn't available.